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Background
cGMP signaling inhibits pathologic cardiac hypertrophy
and remodeling in vivo. In prior studies, we explored the
role of the cGMP-dependent protein kinase I alpha
(PKGIa) in regulating cardiac remodeling by studying
mice with mutations in the PKGIa leucine zipper (LZ)
domain [1], in which PKGIa kinase activity is retained but
LZ-mediated protein-protein interactions are abolished.
These mice (termed leucine zipper mutant, or LZM, mice)
develop accelerated contractile dysfunction, and increased
hypertrophy and mortality in response to LV pressure
overload induced by Transaortic constriction, (TAC) [2],
supporting a critical role for PKGIa in inhibiting remodel-
ing in vivo. The specific myocardial signaling pathways
regulated through PKGIa LZ-mediated interactions
remain unknown. Cardiac JNK activation is required for
normal LV compensation to TAC, and in vitro studies
support a role of PKGIa in activating JNK in the cardiac
myocyte. We hypothesized that PKGIa inhibits TAC-
induced remodeling through activation of JNK in the
heart. To test this, we explored JNK activation in LZM
mouse hearts in response to various durations of TAC.
Results
JNK activation (phosphorylation) increased from 1.0 ±
0.3 ADUs in WT sham hearts to 3.5 ± 0.6 ADUs in WT
48 hour TAC hearts (p<0.001). However, JNK phos-
phorylation did not increase significantly in LZM hearts
post TAC (0.5 ± 0.1 ADU in LZM sham hearts vs 1.3 ±
0.2 ADU in LZM 48 hour TAC hearts, p=ns LZM sham
vs LZM TAC; p<0.001 WT TAC vs LZM TAC). Similar
trends in JNK phosphorylation were observed at 24
hours post-TAC and 7 days post-TAC. Loss of TAC-
induced JNK phosphorylation in LZM mice was accom-
panied by decreased TAC-induced activation of MAP
Kinase Kinase 4 (MKK4) compared with WT controls at
48 hours post-TAC.
We next explored upstream JNK regulators as potential
novel PKGIa interacting molecules. In GST pulldown
experiments with cardiac lysates from WT or LZM mice,
the MAPKKK Mixed Lineage Kinase 3 (MLK3) bound to
the WT PKGIa LZ domain, but not the mutant PKGIa
LZ domain, supporting complex formation between
PKGIa LZ and MLK3. Immunoprecipitation studies with
WT cardiac lysates confirmed an interaction between
these two signaling molecules. We next tested whether
MLK3 is required for cGMP-PKGI-dependent JNK activa-
tion in cultured adult mouse cardiac myocytes (CM) fol-
lowing siRNA knockdown of MLK3. MLK3 knockdown
blocked 8-Bromo-cGMP-stimulated JNK activation, while
control siRNA had no effect on 8-Bromo-cGMP-stimu-
lated JNK activation.
Conclusion
These findings support that the cGMP pathway recruits
the JNK signaling pathway by complex formation
between PKGIa and MLK3, leading to activation of
MKK4 and JNK in the heart. These findings define a
novel mechanism by which cGMP and PKGIa inhibit
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